• Natera outlined new clinical evidence for its Prospera transplant monitoring test ahead of the American Transplant Congress on June 20-24, 2026.
• Results will be presented at the meeting, led by updated readouts from the PEDAL and ProActive kidney-transplant studies.
• PEDAL data indicate elevated Prospera results can flag higher risk of later graft deterioration even when biopsies do not show rejection.
• ProActive findings suggest persistently low Prospera readings align with durable graft stability, supporting more confident immunosuppression management decisions.
• The company plans additional presentations spanning kidney, heart, lung, pancreas, and multi-organ transplants, positioning Prospera for broader routine surveillance use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606180600BIZWIRE_USPR_____20260618_BW969671) on June 18, 2026, and is solely responsible for the information contained therein.